Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 3/20 | 0.52 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.47 |
| ▸ | TAS2R8 | Q9NYW2 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19923622 | 0.90 | SMO (0.53) | SMOEHMT2TAS2R8KMT2AMEN1 | |
| SCHEMBL19923475 | 0.84 | EHMT2 (0.46) | SMOEHMT2KMT2AMEN1TSHR | |
| SCHEMBL19923567 | 0.84 | SMO (0.56) | SMOEHMT2TAS2R8KMT2AMEN1 | |
| SCHEMBL19923417 | 0.83 | EHMT2 (0.45) | SMOEHMT2KMT2AMEN1TSHR | |
| SCHEMBL19923769 | 0.81 | SMO (0.53) | SMOEHMT2TAS2R8KMT2AMEN1 | |
| SCHEMBL19923466 | 0.78 | L3MBTL1 (0.33) | GAAL3MBTL1 | |
| SCHEMBL19923411 | 0.77 | CYP1A2 (0.42) | SMOKMT2AMEN1MAPTMAPK1 | |
| SCHEMBL19923759 | 0.75 | SMO (0.60) | SMOEHMT2KMT2AMEN1 | |
| SCHEMBL19923710 | 0.74 | EHMT2 (0.47) | SMOEHMT2KMT2AMEN1TSHR | |
| SCHEMBL19923492 | 0.73 | EHMT2 (0.46) | SMOEHMT2KMT2AMEN1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10899718-B2 | Polymers functionalized with N-protected hydantoin compounds | BRIDGESTONE CORPORATION (JP) | 2021-01-26 | — | — | US | claimed |
| US-20180065935-A1 | POLYMERS FUNCTIONALIZED WITH N-PROTECTED HYDANTOIN COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2018-03-08 | — | — | US | claimed |
| US-10899718-B2 | Polymers functionalized with N-protected hydantoin compounds | BRIDGESTONE CORPORATION (JP) | 2021-01-26 | — | — | US | disclosed |
| US-20180065935-A1 | POLYMERS FUNCTIONALIZED WITH N-PROTECTED HYDANTOIN COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180065935-A1 | POLYMERS FUNCTIONALIZED WITH N-PROTECTED HYDANTOIN COMPOUNDS | PARG, HNMT, PARN | SMO 4561/4885EHMT2 54/4885TAS2R8 4102/4885 |
| US-10899718-B2 | Polymers functionalized with N-protected hydantoin compounds | HNMT, PARG, PAM | SMO 4608/4885EHMT2 53/4885TAS2R8 4061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.